1
|
Benbenishty J, Ganz FD, Lautrette A, Jaschinski U, Aggarwal A, Søreide E, Weiss M, Dybwik K, Çizmeci EA, Ackerman RCM, Estebanez-Montiel B, Ricou B, Robertsen A, Sprung CL, Avidan A. Variations in reporting of nurse involvement in end-of-life practices in intensive care units worldwide (ETHICUS-2): A prospective observational study. Int J Nurs Stud 2024; 155:104764. [PMID: 38657432 DOI: 10.1016/j.ijnurstu.2024.104764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2023] [Revised: 03/21/2024] [Accepted: 03/22/2024] [Indexed: 04/26/2024]
Abstract
BACKGROUND ICU nurses are most frequently at the patient's bedside, providing care for both patients and family members. They perform an essential role and are involved in decision-making. Despite this, research suggests that nurses have a limited role in the end-of-life decision-making process and are occasionally not involved. OBJECTIVE Explore global ICU nurse involvement in end of life decisions based on the physician's perceptions and sub-analyses from the ETHICUS-2 study. DESIGN This is a secondary analysis of a prospective multinational, observational study of the ETHICUS-2 study. SETTING End of life decision-making processes in ICU patients were studied during a 6-month period between Sept 1, 2015, and Sept 30, 2016, in 199 ICUs in 36 countries. INTERVENTION None. METHODS The ETHICUS II study instrument contained 20 questions. This sub-analysis addressed the four questions related to nurse involvement in end-of-life decision-making: Who initiated the end-of-life discussion? Was withholding or withdrawing treatment discussed with nurses? Was a nurse involved in making the end-of-life decision? Was there agreement between physicians and nurses? These 4 questions are the basis for our analysis. Global regions were compared. RESULTS Physicians completed 91.8 % of the data entry. A statistically significant difference was found between regions (p < 0.001) with Northern Europe and Australia/New Zealand having the most discussion with nurses and Latin America, Africa, Asia and North America the least. The percentages of end-of-life decisions in which nurses were involved ranged between 3 and 44 %. These differences were statistically significant. Agreement between physicians and nurses related to decisions resulted in a wide range of responses (27-86 %) (p < 0.001). There was a wide range of those who replied "not applicable" to the question of agreement between physicians and nurses on EOL decisions (0-41 %). CONCLUSION There is large variability in nurse involvement in end-of-life decision-making in the ICU. The most concerning findings were that in some regions, according to physicians, nurses were not involved in EOL decisions and did not initiate the decision-making process. There is a need to develop the collaboration between nurses and physicians. Nurses have valuable contributions for best possible patient-centered decisions and should be respected as important parts of the interdisciplinary team. TWEETABLE ABSTRACT Wide global differences were found in nurse end of life decision involvement, with low involvement in North and South America and Africa and higher involvement in Europe and Australia/New Zealand.
Collapse
|
2
|
Ringer SK, Schmid A, Weiss M, Ohlerth S, Spielmann N, Clausen NG. Non-surgical external jugular vein catheterization using an ear vein access in piglets. Lab Anim 2023; 57:642-649. [PMID: 37077144 DOI: 10.1177/00236772231167224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/21/2023]
Abstract
The objective of this study was to investigate the feasibility of external jugular vein catheterization through an ear vein in piglets. Forty-six sevoflurane-midazolam anaesthetized piglets were included. External jugular vein catheterization was conducted through the ear vein using the Seldinger technique. Part 1 (n = 27): optimal puncture site was based on the deltoid tuberosity as a landmark to reach the external jugular vein. The final position of the catheter was verified in 25 piglets using computer tomography. Catheterization time was recorded and patency of the catheter assessed by repeated blood sampling for up to 4 h. Part 2 (n = 19): ear vein catheterization was without taking into account any landmarks. Functionality for blood sampling was evaluated as described in part 1. Catheter advancement was possible in 25/27 and 18/19 piglets in parts 1 and 2, respectively. Median (range) time required for successful catheterization was 1.95 (1-10) min (n = 38). The deltoid tuberosity was a good landmark to reach the external jugular vein. But blood sampling was also possible through catheters ending slightly cranial to the external jugular vein. Despite successful catheter advancement, blood sampling was not possible from one catheter in each part of the study (total: two piglets). One of these catheters presented luminal damage, while the other one presented as normal after being removed from the animal. Summarizing, central vein catheterization through the ear vein was feasible in 93.5% and repeated blood sampling was possible in 89.1% of the piglets (n = 46).
Collapse
|
3
|
Denke C, Jaschinski U, Riessen R, Bercker S, Spies C, Ragaller M, Weiss M, Dey K, Michalsen A, Briegel J, Pohrt A, Sprung CL, Avidan A, Hartog CS. End-of-life practices in 11 German intensive care units : Results from the ETHICUS-2 study. Med Klin Intensivmed Notfmed 2023; 118:663-673. [PMID: 36169693 PMCID: PMC10624715 DOI: 10.1007/s00063-022-00961-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Revised: 08/09/2022] [Accepted: 08/30/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND End-of-life care is common in German intensive care units (ICUs) but little is known about daily practice. OBJECTIVES To study the practice of end-of-life care. METHODS Prospectively planned, secondary analysis comprising the German subset of the worldwide Ethicus‑2 Study (2015-2016) including consecutive ICU patients with limitation of life-sustaining therapy or who died. RESULTS Among 1092 (13.7%) of 7966 patients from 11 multidisciplinary ICUs, 967 (88.6%) had treatment limitations, 92 (8.4%) died with failed CPR, and 33 (3%) with brain death. Among patients with treatment limitations, 22.3% (216/967) patients were discharged alive from the ICU. More patients had treatments withdrawn than withheld (556 [57.5%] vs. 411 [42.5%], p < 0.001). Patients with treatment limitations were older (median 73 years [interquartile range (IQR) 61-80] vs. 68 years [IQR 54-77]) and more had mental decision-making capacity (12.9 vs. 0.8%), advance directives (28.6 vs. 11.2%), and information about treatment wishes (82.7 vs 33.3%, all p < 0.001). Physicians reported discussing treatment limitations with patients with mental decision-making capacity and families (91.3 and 82.6%, respectively). Patient wishes were unknown in 41.3% of patients. The major reason for decision-making was unresponsiveness to maximal therapy (34.6%). CONCLUSIONS Treatment limitations are common, based on information about patients' wishes and discussion between stakeholders, patients and families. However, our findings suggest that treatment preferences of nearly half the patients remain unknown which affects guidance for treatment decisions.
Collapse
|
4
|
Eckelmann BJ, Blitzer GC, Smilowitz JB, Trask D, Weiss M, Weber S, Abbott D, Varley P, Neuman H, Maloney JD, Hinshaw JL, Morris BA, Merfeld E, Howard SP, Bradley KA, Baschnagel AM, Bassetti MF, Hennessey DW, Morris Z. Initial Results of a Phase II Trial of Hypofractionated Radiation Therapy for Inoperable Soft Tissue Sarcoma. Int J Radiat Oncol Biol Phys 2023; 117:S147-S148. [PMID: 37784374 DOI: 10.1016/j.ijrobp.2023.06.564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) For patients with soft tissue sarcoma (STS) who cannot or choose not to have surgery, radiation can provide local tumor control in both palliative and definitive settings. Conventionally fractionated radiation provides modest (< 50%) rates of local control (LC) for STS at 2 years. To our knowledge, no prospective studies to date have evaluated the safety and efficacy of dose-escalated hypofractionated radiation therapy as treatment of inoperable STS. We hypothesized that dose-escalated, hypofractionated radiation therapy (RT) for inoperable STS could achieve higher rates of LC than reported in trials of conventionally fractionated RT. MATERIALS/METHODS An IRB-approved single institution prospective phase II clinical trial of dose-escalated, hypofractionated RT as local control for STS was designed and completed planned accrual. Exclusion criteria included anti-cancer systemic therapy within the preceding two weeks. Patients underwent hypofractionated RT utilizing either CT-guided radiation (24, 50%) or MRI-guided radiation treatments (24, 50%). Data on patient characteristics, RT dose and fractionation, LC, toxicity, and overall survival (OS) was collected. The primary endpoint was local tumor control (stable, partial, or complete response according to RECIST) at 2-years after completion of radiation. Secondary endpoints were acute and late toxicity, rates of complete response, 5-year local tumor control, and progression-free and overall survival. Acute toxicity was graded on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale during treatment and at 3 months following RT. RESULTS Forty-eight patients were enrolled, 17 with non-metastatic localized disease and 31 with metastatic disease. Median patient age was 64. Twenty-five men and 23 women were treated. Ninety-six total lesions were treated (36 lung, 7 extremity, 37 abdominopelvic, 16 other). Radiation dose per fraction ranged from 6-12 Gy for a total of 1-12 fractions (median dose was 52.5 Gy in 6 fractions. Median patient follow-up is 8.6 months (range 1 - 36 months). Six patients (13%) did not complete initial 3-month follow-up imaging. Of the 40 patients who have undergone 3-month follow up imaging, 32 (80%) had stable disease, 5 (12.5%) had partial response, 0 had complete response, and 3 (7.5%) had disease progression. Median PFS was 17.2 months at time of last follow up. Median OS was 12.9 months at time of last follow up. Twenty-five patients (52%) experienced an acute toxicity likely or possibly related to radiation. Three (6%) patients experienced CTACE grade 3 or greater treatment-related toxicity (pain, weakness, decreased range of motion, dermatitis). CONCLUSION In this initial report of a prospective, single-institution clinical trial of hypofractionated RT for STS not undergoing resection, we report low rates of acute grade 3 or greater toxicity and high rates of tumor response. We will continue to follow these patients to assess late toxicity and durability of tumor control.
Collapse
|
5
|
Weiss M, Holzer MT, Muehlensiepen F, Ignatyev Y, Fiehn C, Bauhammer J, Schmidt J, Schlüter S, Dihkan A, Scheibner D, Schneider U, Valor-Mendez L, Corte G, Gupta L, Chinoy H, Lundberg I, Cavagna L, Distler JHW, Schett G, Knitza J. Healthcare utilization and unmet needs of patients with antisynthetase syndrome: An international patient survey. Rheumatol Int 2023; 43:1925-1934. [PMID: 37452880 PMCID: PMC10435645 DOI: 10.1007/s00296-023-05372-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Accepted: 06/12/2023] [Indexed: 07/18/2023]
Abstract
Antisynthease syndrome (ASSD) is a rare, complex and understudied autoimmune disease. Internet-based studies can overcome barriers of traditional on-site research and are therefore very appealing for rare diseases. The aim of this study was to investigate patient-reported symptoms, diagnostic delay, symptoms, medical care, health status, working status, disease knowledge and willingness to participate in research of ASSD patients by conducting an international web-based survey. The multilingual questionnaire was created by an international group of rheumatologists and patients and distributed online. 236 participants from 22 countries completed the survey. 184/236 (78.0%) were female, mean age (SD) was 49.6 years (11.3) and most common antisynthetase antibody was Jo-1 (169/236, 71.6%). 79/236 (33.5%) reported to work full-time. Median diagnostic delay was one year. The most common symptom at disease onset was fatigue 159/236 (67.4%), followed by myalgia 130/236 (55.1%). The complete triad of myositis, arthritis and lung involvement verified by a clinician was present in 42/236 (17.8%) at disease onset and in 88/236 (37.3%) during the disease course. 36/236 (15.3%) reported to have been diagnosed with fibromyalgia and 40/236 (16.3%) with depression. The most reported immunosuppressive treatments were oral corticosteroids 179/236 (75.9%), followed by rituximab 85/236 (36.0%). 73/236 (30.9%) had received physiotherapy treatment. 71/236 (30.1%) reported to know useful online information sources related to ASSD. 223/236 (94.5%) were willing to share health data for research purposes once a year. Our results reiterate that internet-based research is invaluable for cooperating with patients to foster knowledge in rare diseases.
Collapse
|
6
|
Blitzer GC, Glazer T, Gustafson S, Burr A, Mattison R, Ganz O, Meyers R, McDowell K, Weiss M, Nickel KP, Chappell RJ, Pulia N, Gallipeau J, Kimple RJ. A Pilot, First in Human Study of Autologous IFN-Gamma Stimulated Mesenchymal Stromal Cells for Treatment of Radiation-Induced Xerostomia. Int J Radiat Oncol Biol Phys 2023; 117:S152. [PMID: 37784385 DOI: 10.1016/j.ijrobp.2023.06.573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) There are no existing effective treatments for radiation-induced xerostomia (RIX), a common side effect of head and neck radiation. Mesenchymal stromal cells (MSCs) exhibit regenerative effects in multiple tissues and may represent an effective cell therapy for the treatment of RIX. Here we present the primary safety and secondary efficacy endpoints of a first-in-human pilot study of IFNγ-stimulated autologous bone marrow- derived MSCs [MSC(M)] for the treatment of RIX. MATERIALS/METHODS We conducted a single-center clinical trial investigating the safety and tolerability of autologous IFNγ-stimulated MSC(M). The study was conducted under an FDA-IND and approved by the local IRB. Patients underwent bone marrow aspiration, MSC(M) were then culture-expanded, stimulated with IFNγ, and cryopreserved. Banked IFNγ-stimulated MSC(M) were thawed, allowed to recover, and then 10 × 106 MSC(M) were injected transcutaneously via ultrasound guidance into one submandibular gland. The primary objective was safety and tolerability determined by dose-limiting toxicity (DLT) defined as submandibular pain > 5 on a standard 10-point pain scale or any serious adverse event (SAE) within one month after injection. Secondary objectives included analysis of efficacy as measured by salivary quantification and using 3 validated quality of life instruments. Quantitative results are reported as mean and standard deviation (SD). RESULTS Six radiation-induced xerostomia patients with head and neck cancer who had completed radiation at least 2 years earlier were enrolled. The median age was 71 (61-74) and 5 (83%) patients were male. Five patients (83%) were treated with chemoradiation and one patient (17%) with radiation alone. The average dose of radiation to the injected submandibular gland was 59.9 Gy. Three patients (50%) reported a pain score of 1 after submandibular gland injection, all pain resolved within 4 days. No patients reported pain 1 month after injection, with no SAEs or other DLTs reported 1 month after injection. The analysis of secondary endpoints demonstrated a trend of increased salivary production. The mean unstimulated saliva was 0.13 mL/min (SD 0.17) at baseline and increased to 0.14 mL/min (SD 0.12) at 1 month after injection and 0.19 mL/min (SD 0.21) at 3-months. Quality of life surveys also showed a trend towards improvement. CONCLUSION Injection of autologous IFNγ-stimulated MSC(M) into the submandibular gland of patients with RIX is safe and well tolerated. A trend towards an improvement in secondary endpoints of salivary quantity and quality of life was observed. This first-in-human pilot study provides support for further investigation into IFNγ-stimulated MSC(M) as an innovative, potentially curative, remedy to treat RIX. A phase I dose-escalation study injecting into bilateral submandibular glands is scheduled to begin accrual in the spring of 2023.
Collapse
|
7
|
Hammersen J, Birndt S, Döhner K, Reuken P, Stallmach A, Sauerbrey P, La Rosée F, Pfirrmann M, Fabisch C, Weiss M, Träger K, Bremer H, Russo S, Illerhaus G, Drömann D, Schneider S, La Rosée P, Hochhaus A. The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial. Leukemia 2023; 37:1879-1886. [PMID: 37507425 PMCID: PMC10457200 DOI: 10.1038/s41375-023-01979-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Revised: 07/12/2023] [Accepted: 07/19/2023] [Indexed: 07/30/2023]
Abstract
Dysregulated hyperinflammatory response is key in the pathogenesis in patients with severe COVID-19 leading to acute respiratory distress syndrome and multiorgan failure. Whilst immunosuppression has been proven to be effective, potential biological targets and optimal timing of treatment are still conflicting. We sought to evaluate efficacy and safety of the Janus Kinase 1/2 inhibitor ruxolitinib, employing the previously developed COVID-19 Inflammation Score (CIS) in a prospective multicenter open label phase II trial (NCT04338958). Primary objective was reversal of hyperinflammation (CIS reduction of ≥25% at day 7 in ≥20% of patients). In 184 patients with a CIS of ≥10 (median 12) ruxolitinib was commenced at an initial dose of 10 mg twice daily and applied over a median of 14 days (range, 2-31). On day 7, median CIS declined to 6 (range, 1-13); 71% of patients (CI 64-77%) achieved a ≥25% CIS reduction accompanied by a reduction of markers of inflammation. Median cumulative dose was 272.5 mg/d. Treatment was well tolerated without any grade 3-5 adverse events related to ruxolitinib. Forty-four patients (23.9%) died, all without reported association to study drug. In conclusion, ruxolitinib proved to be safe and effective in a cohort of COVID-19 patients with defined hyperinflammation.
Collapse
|
8
|
d’Almeida S, Markovic S, Hermann P, Bracht H, Peifer J, Ettrich TJ, Imhof A, Zhou S, Weiss M, Viardot A, Rottbauer W, Dahme T. Thromboembolism after Astra Zeneca COVID-19 vaccine: Not always PF4- antibody mediated. Hum Vaccin Immunother 2023; 19:2252239. [PMID: 37655367 PMCID: PMC10478733 DOI: 10.1080/21645515.2023.2252239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Revised: 07/26/2023] [Accepted: 08/11/2023] [Indexed: 09/02/2023] Open
Abstract
Cases of thromboembolic events in 2021 flared up the discussion about the safety of Astra Zeneca's AZD1222 vaccine. We hereby report three cases of pulmonary embolism (PE), one case of extended portal vein thrombosis, and one case of combined portal vein thrombosis and PE within 2 weeks after vaccination with the Astra Zeneca AZD1222 vaccine in a 60-year-old, a 50-year old, a 33-year-old, a 30-year old, and a 40-year-old male in that year. All patients were healthy before. In three patients, we observed thrombocytopenia and to some extent unusually low antibody levels for the Spike Protein (S-protein), while the other two had normal thrombocyte counts. Only one patient had anti-platelet factor 4 (PF4)-antibodies detectable as it has been described in the "heparin-induced thrombocytopenia (HIT)-like" disease of "vaccine-induced prothrombotic immune thrombocytopenia" (VIPIT) and we therefore assume that heterogeneous mechanisms led to PE. Therefore, we advise to collect and report more cases, in order to determine the age-related risks of vaccination balanced against the benefits of immunity to SARS-COV-2 for the AZD1222 vaccine in order to gain knowledge for the next pandemic.
Collapse
|
9
|
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Althueser L, Andrieu B, Angelino E, Angevaare JR, Antochi VC, Antón Martin D, Arneodo F, Baudis L, Baxter AL, Bazyk M, Bellagamba L, Biondi R, Bismark A, Brookes EJ, Brown A, Bruenner S, Bruno G, Budnik R, Bui TK, Cai C, Cardoso JMR, Cichon D, Cimental Chavez AP, Colijn AP, Conrad J, Cuenca-García JJ, Cussonneau JP, D'Andrea V, Decowski MP, Di Gangi P, Di Pede S, Diglio S, Eitel K, Elykov A, Farrell S, Ferella AD, Ferrari C, Fischer H, Flierman M, Fulgione W, Fuselli C, Gaemers P, Gaior R, Gallo Rosso A, Galloway M, Gao F, Glade-Beucke R, Grandi L, Grigat J, Guan H, Guida M, Hammann R, Higuera A, Hils C, Hoetzsch L, Hood NF, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Joy A, Kato N, Kara M, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Kuger F, Landsman H, Lang RF, Levinson L, Li I, Li S, Liang S, Lindemann S, Lindner M, Liu K, Loizeau J, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Müller J, Ni K, Oberlack U, Paetsch B, Palacio J, Peres R, Peters C, Pienaar J, Pierre M, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Singh R, Sanchez L, Dos Santos JMF, Sarnoff I, Sartorelli G, Schreiner J, Schulte D, Schulte P, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shi S, Shockley E, Silva M, Simgen H, Takeda A, Tan PL, Terliuk A, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Wu VHS, Xing Y, Xu D, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhong M, Zhu T. First Dark Matter Search with Nuclear Recoils from the XENONnT Experiment. PHYSICAL REVIEW LETTERS 2023; 131:041003. [PMID: 37566859 DOI: 10.1103/physrevlett.131.041003] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 06/22/2023] [Indexed: 08/13/2023]
Abstract
We report on the first search for nuclear recoils from dark matter in the form of weakly interacting massive particles (WIMPs) with the XENONnT experiment, which is based on a two-phase time projection chamber with a sensitive liquid xenon mass of 5.9 ton. During the (1.09±0.03) ton yr exposure used for this search, the intrinsic ^{85}Kr and ^{222}Rn concentrations in the liquid target are reduced to unprecedentedly low levels, giving an electronic recoil background rate of (15.8±1.3) events/ton yr keV in the region of interest. A blind analysis of nuclear recoil events with energies between 3.3 and 60.5 keV finds no significant excess. This leads to a minimum upper limit on the spin-independent WIMP-nucleon cross section of 2.58×10^{-47} cm^{2} for a WIMP mass of 28 GeV/c^{2} at 90% confidence level. Limits for spin-dependent interactions are also provided. Both the limit and the sensitivity for the full range of WIMP masses analyzed here improve on previous results obtained with the XENON1T experiment for the same exposure.
Collapse
|
10
|
Aprile E, Abe K, Ahmed Maouloud S, Althueser L, Andrieu B, Angelino E, Angevaare JR, Antochi VC, Antón Martin D, Arneodo F, Baudis L, Baxter AL, Bazyk M, Bellagamba L, Biondi R, Bismark A, Brookes EJ, Brown A, Bruenner S, Bruno G, Budnik R, Bui TK, Cai C, Cardoso JMR, Cichon D, Cimental Chavez AP, Clark M, Colijn AP, Conrad J, Cuenca-García JJ, Cussonneau JP, D'Andrea V, Decowski MP, Di Gangi P, Di Pede S, Diglio S, Eitel K, Elykov A, Farrell S, Ferella AD, Ferrari C, Fischer H, Flierman M, Fulgione W, Fuselli C, Gaemers P, Gaior R, Gallo Rosso A, Galloway M, Gao F, Glade-Beucke R, Grandi L, Grigat J, Guan H, Guida M, Hammann R, Higuera A, Hils C, Hoetzsch L, Hood NF, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Joy A, Kato N, Kara M, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Kuger F, Landsman H, Lang RF, Levinson L, Li I, Li S, Liang S, Lindemann S, Lindner M, Liu K, Loizeau J, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Müller J, Ni K, Oberlack U, Paetsch B, Palacio J, Pellegrini Q, Peres R, Peters C, Pienaar J, Pierre M, Pizzella V, Plante G, Pollmann TR, Qi J, Qin J, Ramírez García D, Singh R, Sanchez L, Dos Santos JMF, Sarnoff I, Sartorelli G, Schreiner J, Schulte D, Schulte P, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shi S, Shockley E, Silva M, Simgen H, Takeda A, Tan PL, Terliuk A, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Wu VHS, Xing Y, Xu D, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhong M, Zhu T. Searching for Heavy Dark Matter near the Planck Mass with XENON1T. PHYSICAL REVIEW LETTERS 2023; 130:261002. [PMID: 37450817 DOI: 10.1103/physrevlett.130.261002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 06/07/2023] [Accepted: 06/07/2023] [Indexed: 07/18/2023]
Abstract
Multiple viable theoretical models predict heavy dark matter particles with a mass close to the Planck mass, a range relatively unexplored by current experimental measurements. We use 219.4 days of data collected with the XENON1T experiment to conduct a blind search for signals from multiply interacting massive particles (MIMPs). Their unique track signature allows a targeted analysis with only 0.05 expected background events from muons. Following unblinding, we observe no signal candidate events. This Letter places strong constraints on spin-independent interactions of dark matter particles with a mass between 1×10^{12} and 2×10^{17} GeV/c^{2}. In addition, we present the first exclusion limits on spin-dependent MIMP-neutron and MIMP-proton cross sections for dark matter particles with masses close to the Planck scale.
Collapse
|
11
|
Weiss M, Assier H, Hotz C, Hua C, Thomas L, Wolkenstein P, Ingen-Housz-Oro S. Acute generalized exanthematous pustulosis: Clinico-biological profile and inducing drugs in 83 patients. J Eur Acad Dermatol Venereol 2023; 37:e776-e778. [PMID: 36734481 DOI: 10.1111/jdv.18940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Accepted: 02/01/2023] [Indexed: 02/04/2023]
|
12
|
Dupree J, Dunn RL, Yan P, Suh D, Marsh EE, Dalton V, Norton EC, Weiss M. Impact of different legislative in-vitro fertilization coverage mandates on male infertility care. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00276-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
13
|
Ning D, Garg K, Mayer B, Schick B, Bracht H, Barth E, Weiss M, Li C, Schneider J, Schneider EM. Monocyte subtype expression patterns in septic patients with diabetes are distinct from patterns observed in obese patients. Front Med (Lausanne) 2023; 9:1026298. [PMID: 36687421 PMCID: PMC9849690 DOI: 10.3389/fmed.2022.1026298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Accepted: 11/29/2022] [Indexed: 01/06/2023] Open
Abstract
Background Sepsis causes a high rate of mortality and long-term morbidity, associated with an imbalance of innate immunity against infections and inflammation. Obesity and diabetes increase the risk for disease severity. Monocyte dysfunction plays a major role and justify further investigations. Objective To investigate the distribution and inflammatory phenotypes in circulating monocyte subsets in patients manifesting with sepsis including septic shock with and without obesity and diabetes. Methods A total of 235 blood samples were tested from critically ill adult patients registered at the intensive care unit (ICU). The cohorts were divided into non-diabetic groups with or without obesity and diabetic groups with or without obesity, suffering from sepsis or septic shock. We determined frequencies of total monocytes and of monocyte subsets in the circulation and density expression levels of functional markers, including CD14, CD16, HLA-DR, CD33, CD163, CD206, and arginase-1 by flow cytometric analysis. Results When progressing to septic shock in non-diabetic and diabetic patients, the percentages of total monocytes among the leukocyte population and of CD33+ and CD14+ monocytes among the monocyte population were consistently down-regulated compared to non-sepsis in non-diabetic and diabetic patients, respectively. Non-diabetic sepsis patients further presented with decreased CD33 and up-regulated CD163 expression density, which was absent in diabetic patients. We subsequently addressed obesity-related changes of monocytes in non-diabetic and diabetic septic patients. Obese septic patients with diabetes were unique in displaying increased monocytic CD16 and CD163 expression. However, obese septic patients without diabetes solely presented with lower amounts of non-classical monocytes. Body mass index (BMI) dependent changes were restricted to diabetic septic patients, with a significantly higher diminution of the classical monocyte subset and concomitantly increased CD16 expression densities. Conclusion Distribution and phenotypes of monocyte subsets were differentially modulated in critically ill patients with and without metabolic disease when progressing to sepsis or septic shock. Only diabetic septic patients displayed decline of classical monocytes and increase of CD16 expression densities. Therefore, diabetes but not obesity appears to promote the inflammatory phenotype of circulating monocytes in critically ill patients.
Collapse
|
14
|
Porzsolt F, Weiß C, Weiss M. [Covid-19: Twin Method for Verifying Real-World Effectiveness Under Everyday Conditions]. DAS GESUNDHEITSWESEN 2023; 85:22-25. [PMID: 35738304 DOI: 10.1055/a-1819-6237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The positive side of the Covid-19 pandemic is that it has provided a stimulation for innovations. As an example, we discuss the Pragmatic Controlled Trial (PCT), a twin study that can be used to confirm the real-world effectiveness (RWE) of health services under the non-standardized conditions of everyday care. Proof of the RWE could generally be important for health services with conditional approval. The PCT uses the Bayesian principle instead of randomization. It enables care under non-standardized everyday conditions and, by describing the endpoint-specific risks of each individual patient and by classifying the interventions, creates an unbiased evaluation in a non-experimental, but risk-stratified and controlled study. Patients expect a timely solution to their health problems. Until now, science has required sufficiently well-founded results before approving an innovation. The Covid-19 pandemic has shown that the demand for immediate and best possible care can be met through the conditional approval of a new care principle. With the PCT, we describe a procedure with which, after conditional approval, the missing data can be collected in order to successfully complete the approval process.
Collapse
|
15
|
Boksán K, Dechant M, Weiss M, Hellwig A, Stemmler M. A meta-analysis on the effects of incarceration-based opioid substitution treatment. MEDICINE, SCIENCE, AND THE LAW 2023; 63:53-60. [PMID: 35934979 DOI: 10.1177/00258024221118971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: Opioid substitution treatment (OST) is a common treatment for individuals who use opioids; however, empirical evidence on the effects of OST during incarceration is scarce. Our aim was to conduct a meta-analysis on the effects of incarceration-based OST on substance use, treatment engagement post-release and re-incarceration. Method: We searched for studies on individuals who were incarcerated and treated with OST, compared to a comparison group. Studies were only included if they reported data post-release. Results: N = 15 studies met the inclusion criteria. We found less opioid use, less other drug use, higher treatment engagement post-release and less re-incarceration among treated individuals compared to the comparison group. Moderator analyses showed some influence of length of follow-up period and study quality. Conclusions: Incarceration-based OST reduces drug use, re-incarceration and leads to higher treatment engagement after release. More research is needed on the effects of incarceration-based OST on secondary outcomes (e.g. health and social integration) and on factors that moderate these effects.
Collapse
|
16
|
Körper S, Grüner B, Zickler D, Wiesmann T, Wuchter P, Blasczyk R, Zacharowski K, Spieth P, Tonn T, Rosenberger P, Paul G, Pilch J, Schwäble J, Bakchoul T, Thiele T, Knörlein J, Dollinger MM, Krebs J, Bentz M, Corman VM, Kilalic D, Schmidtke-Schrezenmeier G, Lepper PM, Ernst L, Wulf H, Ulrich A, Weiss M, Kruse JM, Burkhardt T, Müller R, Klüter H, Schmidt M, Jahrsdörfer B, Lotfi R, Rojewski M, Appl T, Mayer B, Schnecko P, Seifried E, Schrezenmeier H. One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. J Clin Invest 2022; 132:163657. [PMID: 36326824 PMCID: PMC9753994 DOI: 10.1172/jci163657] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Accepted: 10/18/2022] [Indexed: 11/06/2022] Open
Abstract
BACKGROUNDResults of many randomized trials on COVID-19 convalescent plasma (CCP) have been reported, but information on long-term outcome after CCP treatment is limited. The objectives of this extended observation of the randomized CAPSID trial are to assess long-term outcome and disease burden in patients initially treated with or without CCP.METHODSOf 105 randomized patients, 50 participated in the extended observation. Quality of life (QoL) was assessed by questionnaires and a structured interview. CCP donors (n = 113) with asymptomatic to moderate COVID-19 were included as a reference group.RESULTSThe median follow-up of patients was 396 days, and the estimated 1-year survival was 78.7% in the CCP group and 60.2% in the control (P = 0.08). The subgroup treated with a higher cumulative amount of neutralizing antibodies showed a better 1-year survival compared with the control group (91.5% versus 60.2%, P = 0.01). Medical events and QoL assessments showed a consistent trend for better results in the CCP group without reaching statistical significance. There was no difference in the increase in neutralizing antibodies after vaccination between the CCP and control groups.CONCLUSIONThe trial demonstrated a trend toward better outcome in the CCP group without reaching statistical significance. A predefined subgroup analysis showed a significantly better outcome (long-term survival, time to discharge from ICU, and time to hospital discharge) among those who received a higher amount of neutralizing antibodies compared with the control group. A substantial long-term disease burden remains after severe COVID-19.Trial registrationEudraCT 2020-001310-38 and ClinicalTrials.gov NCT04433910.FundingBundesministerium für Gesundheit (German Federal Ministry of Health).
Collapse
|
17
|
Weiss M, Nikisher B, Haran H, Tefft K, Adams J, Edwards JG. High throughput screen of small molecules as potential countermeasures to galactic cosmic radiation induced cellular dysfunction. LIFE SCIENCES IN SPACE RESEARCH 2022; 35:76-87. [PMID: 36336373 DOI: 10.1016/j.lssr.2022.06.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 05/23/2022] [Accepted: 06/16/2022] [Indexed: 06/16/2023]
Abstract
Space travel increases galactic cosmic ray exposure to flight crews and this is significantly elevated once travel moves beyond low Earth orbit. This includes combinations of high energy protons and heavy ions such as 56Fe or 16O. There are distinct differences in the biological response to low-energy transfer (x-rays) or high-energy transfer (High-LET). However, given the relatively low fluence rate of exposure during flight operations, it might be possible to manage these deleterious effects using small molecules currently available. Virtually all reports to date examining small molecule management of radiation exposure are based on low-LET challenges. To that end an FDA approved drug library (725 drugs) was used to perform a high throughput screen of cultured cells following exposure to galactic cosmic radiation. The H9c2 myoblasts, ES-D3 pluripotent cells, and Hy926 endothelial cell lines were exposed to a single exposure (75 cGy) using the 5-ion GCRsim protocol developed at the NASA Space Radiation Laboratory (NSRL). Following GCR exposure cells were maintained for up to two weeks. For each drug (@10µM), a hierarchical cumulative score was developed incorporating measures of mitochondrial and cellular function, oxidant stress and cell senescence. The top 160 scores were retested following a similar protocol using 1µM of each drug. Within the 160 drugs, 33 are considered to have an anti-inflammatory capacity, while others also indirectly suppressed pro-inflammatory pathways or had noted antioxidant capacity. Lead candidates came from different drug classes that included angiotensin converting enzyme inhibitors or AT1 antagonists, COX2 inhibitors, as well as drugs mediated by histamine receptors. Surprisingly, different classes of anti-diabetic medications were observed to be useful including sulfonylureas and metformin. Using a hierarchical decision structure, we have identified several lead candidates. That no one drug or even drug class was completely successful across all parameters tested suggests the complexity of managing the consequences of galactic cosmic radiation exposure.
Collapse
|
18
|
Holtdirk F, Zindler T, Mehnert A, Bültmann O, Weiss M, Mayer J, Meyer B, Specht A, Bröde P, Claus M, Watzl C, Cheng F. Digital health applications to support patients with breast cancer: Effects of two tailored, dialogue-based programs on quality of life. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01501-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
19
|
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Althueser L, Andrieu B, Angelino E, Angevaare JR, Antochi VC, Antón Martin D, Arneodo F, Baudis L, Baxter AL, Bellagamba L, Biondi R, Bismark A, Brown A, Bruenner S, Bruno G, Budnik R, Bui TK, Cai C, Capelli C, Cardoso JMR, Cichon D, Clark M, Colijn AP, Conrad J, Cuenca-García JJ, Cussonneau JP, D'Andrea V, Decowski MP, Di Gangi P, Di Pede S, Di Giovanni A, Di Stefano R, Diglio S, Eitel K, Elykov A, Farrell S, Ferella AD, Ferrari C, Fischer H, Fulgione W, Gaemers P, Gaior R, Gallo Rosso A, Galloway M, Gao F, Gardner R, Glade-Beucke R, Grandi L, Grigat J, Guida M, Hammann R, Higuera A, Hils C, Hoetzsch L, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Joy A, Kato N, Kara M, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Kuger F, Landsman H, Lang RF, Levinson L, Li I, Li S, Liang S, Lindemann S, Lindner M, Liu K, Loizeau J, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Müller J, Ni K, Oberlack U, Paetsch B, Palacio J, Paschos P, Peres R, Peters C, Pienaar J, Pierre M, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Reichard S, Rocchetti A, Rupp N, Sanchez L, Dos Santos JMF, Sarnoff I, Sartorelli G, Schreiner J, Schulte D, Schulte P, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shi S, Shockley E, Silva M, Simgen H, Stephen J, Takeda A, Tan PL, Terliuk A, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Wei Y, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Xu D, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhong M, Zhu T. Search for New Physics in Electronic Recoil Data from XENONnT. PHYSICAL REVIEW LETTERS 2022; 129:161805. [PMID: 36306777 DOI: 10.1103/physrevlett.129.161805] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 09/21/2022] [Indexed: 06/16/2023]
Abstract
We report on a blinded analysis of low-energy electronic recoil data from the first science run of the XENONnT dark matter experiment. Novel subsystems and the increased 5.9 ton liquid xenon target reduced the background in the (1, 30) keV search region to (15.8±1.3) events/(ton×year×keV), the lowest ever achieved in a dark matter detector and ∼5 times lower than in XENON1T. With an exposure of 1.16 ton-years, we observe no excess above background and set stringent new limits on solar axions, an enhanced neutrino magnetic moment, and bosonic dark matter.
Collapse
|
20
|
Körper S, Schrezenmeier EV, Rincon-Arevalo H, Grüner B, Zickler D, Weiss M, Wiesmann T, Zacharowski K, Kalbhenn J, Bentz M, Dollinger MM, Paul G, Lepper PM, Ernst L, Wulf H, Zinn S, Appl T, Jahrsdörfer B, Rojewski M, Lotfi R, Dörner T, Jungwirth B, Seifried E, Fürst D, Schrezenmeier H. Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19. Front Immunol 2022; 13:1008438. [PMID: 36275695 PMCID: PMC9582990 DOI: 10.3389/fimmu.2022.1008438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2022] [Accepted: 09/12/2022] [Indexed: 12/03/2022] Open
Abstract
Objectives To determine the profile of cytokines in patients with severe COVID-19 who were enrolled in a trial of COVID-19 convalescent plasma (CCP). Methods Patients were randomized to receive standard treatment and 3 CCP units or standard treatment alone (CAPSID trial, ClinicalTrials.gov NCT04433910). The primary outcome was a dichotomous composite outcome (survival and no longer severe COVID-19 on day 21). Time to clinical improvement was a key secondary endpoint. The concentrations of 27 cytokines were measured (baseline, day 7). We analyzed the change and the correlation between serum cytokine levels over time in different subgroups and the prediction of outcome in receiver operating characteristics (ROC) analyses and in multivariate models. Results The majority of cytokines showed significant changes from baseline to day 7. Some were strongly correlated amongst each other (at baseline the cluster IL-1ß, IL-2, IL-6, IL-8, G-CSF, MIP-1α, the cluster PDGF-BB, RANTES or the cluster IL-4, IL-17, Eotaxin, bFGF, TNF-α). The correlation matrix substantially changed from baseline to day 7. The heatmaps of the absolute values of the correlation matrix indicated an association of CCP treatment and clinical outcome with the cytokine pattern. Low levels of IP-10, IFN-γ, MCP-1 and IL-1ß on day 0 were predictive of treatment success in a ROC analysis. In multivariate models, low levels of IL-1ß, IFN-γ and MCP-1 on day 0 were significantly associated with both treatment success and shorter time to clinical improvement. Low levels of IP-10, IL-1RA, IL-6, MCP-1 and IFN-γ on day 7 and high levels of IL-9, PDGF and RANTES on day 7 were predictive of treatment success in ROC analyses. Low levels of IP-10, MCP-1 and high levels of RANTES, on day 7 were associated with both treatment success and shorter time to clinical improvement in multivariate models. Conclusion This analysis demonstrates a considerable dynamic of cytokines over time, which is influenced by both treatment and clinical course of COVID-19. Levels of IL-1ß and MCP-1 at baseline and MCP-1, IP-10 and RANTES on day 7 were associated with a favorable outcome across several endpoints. These cytokines should be included in future trials for further evaluation as predictive factors.
Collapse
|
21
|
Schänzler VM, Riedel M, Riedel F, Strizek B, Gembruch U, Weiss M, Mustea A, Egger EK, Recker F. Erratum: PJ – EPAs und die Frauenheilkunde – Evaluation des Ist- und Soll-Zustands und dessen Diskrepanz. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/a-1969-6768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
22
|
Weiss M. Fragment-screening by crystallography at the Helmholtz-Zentrum Berlin – workflow, tools and procedures. Acta Crystallogr A Found Adv 2022. [DOI: 10.1107/s205327332209787x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
23
|
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Alfonsi M, Althueser L, Angelino E, Angevaare JR, Antochi VC, Antón Martin D, Arneodo F, Baudis L, Baxter AL, Bellagamba L, Biondi R, Bismark A, Brown A, Bruenner S, Bruno G, Budnik R, Capelli C, Cardoso JMR, Cichon D, Cimmino B, Clark M, Colijn AP, Conrad J, Cuenca-García JJ, Cussonneau JP, D'Andrea V, Decowski MP, Gangi PD, Pede SD, Giovanni AD, Stefano RD, Diglio S, Elykov A, Farrell S, Ferella AD, Fischer H, Fulgione W, Gaemers P, Gaior R, Galloway M, Gao F, Glade-Beucke R, Grandi L, Grigat J, Higuera A, Hils C, Hiraide K, Hoetzsch L, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Kato N, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Landsman H, Lang RF, Levinson L, Li I, Liang S, Lindemann S, Lindner M, Liu K, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Manfredini A, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Ni K, Oberlack U, Palacio J, Peres R, Pienaar J, Pierre M, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Reichard S, Rocchetti A, Rupp N, Sanchez L, Dos Santos JMF, Sartorelli G, Schreiner J, Schulte D, Schulze Eißing H, Schumann M, Lavina LS, Selvi M, Semeria F, Shagin P, Shockley E, Silva M, Simgen H, Takeda A, Tan PL, Terliuk A, Therreau C, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Wei Y, Weinheimer C, Weiss M, Wenz D, Westermann J, Wittweg C, Wolf T, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhang Y, Zhong M, Zhu T, Zopounidis JP, Laubenstein M, Nisi S. Material radiopurity control in the XENONnT experiment. THE EUROPEAN PHYSICAL JOURNAL. C, PARTICLES AND FIELDS 2022; 82:599. [PMID: 35821975 PMCID: PMC9270421 DOI: 10.1140/epjc/s10052-022-10345-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Accepted: 04/19/2022] [Indexed: 11/18/2022]
Abstract
The selection of low-radioactive construction materials is of the utmost importance for rare-event searches and thus critical to the XENONnT experiment. Results of an extensive radioassay program are reported, in which material samples have been screened with gamma-ray spectroscopy, mass spectrometry, and \documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$^{222}$$\end{document}222Rn emanation measurements. Furthermore, the cleanliness procedures applied to remove or mitigate surface contamination of detector materials are described. Screening results, used as inputs for a XENONnT Monte Carlo simulation, predict a reduction of materials background (\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$\sim $$\end{document}∼17%) with respect to its predecessor XENON1T. Through radon emanation measurements, the expected \documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$^{222}$$\end{document}222Rn activity concentration in XENONnT is determined to be 4.2 (\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$^{+0.5}_{-0.7}$$\end{document}-0.7+0.5) \documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$\upmu $$\end{document}μBq/kg, a factor three lower with respect to XENON1T. This radon concentration will be further suppressed by means of the novel radon distillation system.
Collapse
|
24
|
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Alfonsi M, Althueser L, Angelino E, Angevaare J, Antochi V, Antón Martin D, Arneodo F, Baudis L, Baxter A, Bellagamba L, Bernard A, Biondi R, Bismark A, Brown A, Bruenner S, Bruno G, Budnik R, Capelli C, Cardoso J, Cichon D, Cimmino B, Clark M, Colijn A, Conrad J, Cuenca-García J, Cussonneau J, D’Andrea V, Decowski M, Di Gangi P, Di Pede S, Di Giovanni A, Di Stefano R, Diglio S, Elykov A, Farrell S, Ferella A, Fischer H, Fulgione W, Gaemers P, Gaior R, Galloway M, Gao F, Glade-Beucke R, Grandi L, Grigat J, Higuera A, Hils C, Hoetzsch L, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Joy A, Kato N, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Landsman H, Lang R, Levinson L, Li I, Li S, Liang S, Lindemann S, Lindner M, Liu K, Lombardi F, Long J, Lopes J, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Manfredini A, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Müller J, Ni K, Oberlack U, Paetsch B, Palacio J, Peres R, Pienaar J, Pierre M, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Reichard S, Rocchetti A, Rupp N, Sanchez L, dos Santos J, Sarnoff I, Sartorelli G, Schreiner J, Schulte D, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shi S, Shockley E, Silva M, Simgen H, Takeda A, Tan PL, Terliuk A, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Wei Y, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhang Y, Zhong M, Zhu T, Zopounidis J. Emission of single and few electrons in XENON1T and limits on light dark matter. Int J Clin Exp Med 2022. [DOI: 10.1103/physrevd.106.022001] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
25
|
Parakrama R, Sidiqi B, Demyan L, Pasha S, Pinto D, Zavadsky T, Zou X, Patruni S, Kapusta A, Standring O, Weiss M, Herman J, King D. P-10 Standardization of a neoadjuvant therapy (NAT) pathway for pancreatic cancer across a geographically large and diverse healthcare system improves patient care and successful completion of NAT. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|